News

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...